SMMT logo

Summit Therapeutics Inc. (SMMT)

$14.15

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SMMT

Market cap

$11.32B

EPS

-1.06

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-1.498678

Price on SMMT

Previous close

$15.08

Today's open

$15.20

Day's range

$14.06 - $15.20

52 week range

$12.07 - $29.23

Profile about SMMT

CEO

Robert W. Duggan

Employees

265

Headquarters

Miami, FL

Exchange

NASDAQ Global Market

Shares outstanding

799763918

Issue type

Common Stock

SMMT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SMMT

The FDA declined to approve one of biotech's most closely watched cancer drugs

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

news source

Market Watch • 15 hours ago

news preview

Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles

Summit Therapeutics Inc. (NASDAQ:SMMT) is trading at a 52-week low on Monday after the FDA rejected the company's lead cancer drug application.

news source

Benzinga • 16 hours ago

news preview

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.

news source

Zacks Investment Research • 10 hours ago

news preview

2 Cancer-Drug Developers Seeing Unusual Options Volume

Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory developments.

news source

Schaeffers Research • 10 hours ago

news preview

Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.

news source

Barrons • 15 hours ago

news preview

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.

news source

Investors Business Daily • Nov 15, 2026

news preview

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.

news source

Business Wire • Nov 15, 2026

news preview

Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 62.3% in Summit Therapeutics (SMMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 10, 2026

news preview

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca's $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch.

news source

Business Wire • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Summit Therapeutics Inc.

Open an M1 investment account to buy and sell Summit Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SMMT on M1